BDBM348627 US10577374, Compound 350::US9790229, Compound 350

SMILES Nc1ncnc(N2CC[C@H]([C@@H](C2)N2CC=CC[C@@H](Nc3cc(F)cc(Cl)c3)C2=O)C(F)(F)F)c1F

InChI Key InChIKey=MUKHOOXXWYLWNH-BRWVUGGUSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 348627   

TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Sunesis Pharmaceuticals

US Patent
LigandPNGBDBM348627(US10577374, Compound 350 | US9790229, Compound 350)
Affinity DataIC50: <100nMAssay Description:BTK-POLYGAT-LS ASSAY. The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Sunesis Pharmaceuticals

US Patent
LigandPNGBDBM348627(US10577374, Compound 350 | US9790229, Compound 350)
Affinity DataIC50: <100nMAssay Description:The purpose of the BTK in vitro assay is to determine compound potency against BTK through the measurement of IC50. Compound inhibition is measured a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent